Tag: Novo Nordisk A/S

Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs

Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.

Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly

Here’s an update on our 4th Industrial Revolution stocks and the rest of the portfolio

Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Russia’s war on Ukraine puts women off having children — and that could spell economic disaster

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial

Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China